Literature DB >> 8324644

Analysis of the 11p13 Wilms' tumor suppressor gene (WT1) in ovarian tumors.

W Bruening1, P Gros, T Sato, J Stanimir, Y Nakamura, D Housman, J Pelletier.   

Abstract

We have examined the status of the Wilms' tumor suppressor gene (WT1), residing at chromosome 11 band p13, in a total of 40 cancers of the female reproductive tract. Northern blot analysis revealed that the WT1 gene is expressed in a large percentage of ovarian tumors (75%) analyzed. Single-strand conformation polymorphism analysis was performed on all the tumors in this study in an attempt to detect mutations within the WT1 gene. Only silent mutations were detected within intron 7 of WT1 using this method. Loss of heterozygosity studies were performed at the WT1 locus in several ovarian tumors and revealed that in the informative cases, heterozygosity was retained.

Entities:  

Mesh：

Substances：

Year:  1993        PMID： 8324644     DOI： 10.3109/07357909309018871

Source DB:  PubMed          Journal:  Cancer Invest        ISSN： 0735-7907            Impact factor:   2.176


  14 in total

Review 1.  Wilms' tumor gene WT1: its oncogenic function and clinical application.

Authors:  H Sugiyama
Journal:  Int J Hematol       Date:  2001-02       Impact factor: 2.490

2.  Correlation of germ-line mutations and two-hit inactivation of the WT1 gene with Wilms tumors of stromal-predominant histology.

Authors:  V Schumacher; S Schneider; A Figge; G Wildhardt; D Harms; D Schmidt; A Weirich; R Ludwig; B Royer-Pokora
Journal:  Proc Natl Acad Sci U S A       Date:  1997-04-15       Impact factor: 11.205

3.  Wilms' tumor 1 susceptibility (WT1) gene products are selectively expressed in malignant mesothelioma.

Authors:  K M Amin; L A Litzky; W R Smythe; A M Mooney; J M Morris; D J Mews; H I Pass; C Kari; U Rodeck; F J Rauscher
Journal:  Am J Pathol       Date:  1995-02       Impact factor: 4.307

4.  Recessive oncogenes: current status.

Authors:  Xiang Gao; Kenneth V Honn
Journal:  Pathol Oncol Res       Date:  1995       Impact factor: 3.201

5.  The lck promoter-driven expression of the Wilms tumor gene WT1 blocks intrathymic differentiation of T-lineage cells.

Authors:  Hanfen Li; Yoshihiro Oka; Akihiro Tsuboi; Tamotsu Yamagami; Toru Miyazaki; Sei-ichi Yusa; Kotomi Kawasaki; Yukiko Kishimoto; Momotaro Asada; Hiroko Nakajima; Keisuke Kanato; Sumiyuki Nishida; Tomoki Masuda; Masaki Murakami; Naoki Hosen; Manabu Kawakami; Hiroyasu Ogawa; Fritz Melchers; Ichiro Kawase; Yusuke Oji; Haruo Sugiyama
Journal:  Int J Hematol       Date:  2003-06       Impact factor: 2.490

6.  WT1 marker is not sufficient for distinguishing between melanoma and melanocytic nevi.

Authors:  Karli Rosner; Darius R Mehregan; Darius Moussai; Judith Abrams; Gerard Tromp; David A Mehregan
Journal:  J Cutan Pathol       Date:  2009-07-09       Impact factor: 1.587

Review 7.  Wilms tumor gene (WT1) expression as a panleukemic marker.

Authors:  Hans D Menssen; Jan M Siehl; Eckhard Thiel
Journal:  Int J Hematol       Date:  2002-08       Impact factor: 2.490

Review 8.  Cancer immunotherapy targeting WT1 protein.

Authors:  Haruo Sugiyama
Journal:  Int J Hematol       Date:  2002-08       Impact factor: 2.490

9.  Wilms' tumour-suppressor protein isoforms have opposite effects on Igf2 expression in primary embryonic cells, independently of p53 genotype.

Authors:  A Duarte; A Caricasole; C F Graham; A Ward
Journal:  Br J Cancer       Date:  1998       Impact factor: 7.640

10.  The zinc finger domain of Wilms' tumor 1 suppressor gene (WT1) behaves as a dominant negative, leading to abrogation of WT1 oncogenic potential in breast cancer cells.

Authors:  Youqi Han; Serban San-Marina; Lin Yang; Haytham Khoury; Mark D Minden
Journal:  Breast Cancer Res       Date:  2007       Impact factor: 6.466
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.